nach oben

Journal of Assisted Reproduction and Genetics

Erschienen in:

01.02.2012 | Genetics

Aromatase (CYP19) gene variants influence ovarian response to standard gonadotrophin stimulation

verfasst von: Leandros A. Lazaros, Elissavet G. Hatzi, Nectaria V. Xita, Georgios V. Makrydimas, Apostolos I. Kaponis, Atsushi Takenaka, Ioannis P. Kosmas, Nikolaos V. Sofikitis, Theodoros I. Stefos, Konstantinos A. Zikopoulos, Ioannis A. Georgiou

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The association of cytochrome P450 aromatase gene CYP19(TTTA) _n polymorphism with ovarian response to FSH stimulation was explored.

Methods

Three hundred women undergoing medically assisted reproduction and 300 women with at least one spontaneous pregnancy participated in the study. CYP19(TTTA) _n polymorphism was genotyped, while serum hormones were determined. During oocyte retrieval, the follicular size, the follicle and oocyte numbers were recorded.

Results

Six CYP19(TTTA) _n alleles with 7 to 12 repeats were revealed. Women homozygous for long CYP19(TTTA) _n alleles presented with lower serum FSH levels at the third day of the menstrual cycle (p < 0.001) and higher large follicle numbers (p < 0.01), compared to women homozygous for short CYP19(TTTA) _n alleles. The CYP19(TTTA) ₇ allele was associated with higher serum FSH levels (p < 0.003), with lower total follicle (p < 0.02) and large follicle numbers (p < 0.03), while CYP19(TTTA) ₇ allele-carriers presented more frequently with small follicles than CYP19(TTTA) ₇ allele-non carriers (p < 0.01).

Conclusions

CYP19 genetic variants were associated with ovarian reserve and response to standard gonadotrophin stimulation of women undergoing in vitro fertilization.

Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev. 1994;15:342–55.PubMed

Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril. 1999;72:961–9.PubMedCrossRef

Chen S, Itoh T, Wu K, Zhou D, Yang C. Transcriptional regulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol. 2002;83:93–9.PubMedCrossRef

Ishihara H, Kitawaki J, Kado N, Koshiba H, Fushiki S, Honjo H. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. Fertil Steril. 2003;79:735–42.PubMedCrossRef

Shozu M, Akasofu K, Harada T, Kubota Y. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metabol. 1991;72:560–6.CrossRef

Ludwig M, Beck A, Wickert L, Bolkenius U, Tittel B, Hinkel K, Bidlingmaier F. Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene. J Pediatr Endocrinol Metab. 1998;11:657–64.PubMedCrossRef

Lin L, Ercan O, Raza J, Burren CP, Creighton SM, Auchus RJ, Dattani MT, Achermann JC. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J Clin Endocrinol Metabol. 2007;92:982–90.CrossRef

Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metabol. 1994;78:1287–92.CrossRef

Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H. Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metabol. 1997;82:1739–45.CrossRef

10.

Belgorosky A, Pepe C, Marino R, Guercio G, Saraco N, Vaiani E, Rivarola MA. Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene. J Clin Endocrinol Metabol. 2003;88:5127–31.CrossRef

11.

Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metabol. 1995;80:3689–98.CrossRef

12.

Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metabol. 1999;84:4677–94.CrossRef

13.

Chow JD, Simpson ER, Boon WC. Alternative 5′-untranslated first exons of the mouse Cyp19A1 (aromatase) gene. J Steroid Biochem Mol Biol. 2009;115:115–25.PubMedCrossRef

14.

Lee SJ, Kim WY, Choi JY, Lee SS, Shin JG. Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population. J Hum Genet. 2010;55:189–93.PubMedCrossRef

15.

Altmäe S, Haller K, Peters M, Saare M, Hovatta O, Stavreus-Evers A, Velthut A, Karro H, Metspalu A, Salumets A. Aromatase gene (CYP19A1) variants, female infertility and ovarian stimulation outcome: a preliminary report. Reprod Biomed Online. 2009;18:651–7.PubMedCrossRef

16.

Baghaei F, Rosmond R, Westberg L, Hellstrand M, Eriksson E, Holm G, Bjorntorp P. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women. Obes Res. 2003;11:578–85.PubMedCrossRef

17.

Xita N, Lazaros L, Georgiou I, Tsatsoulis A. CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. Fertil Steril. 2010;94:250–4.PubMedCrossRef

18.

Woods NF, Mitchell ES, Tao Y, Viernes HM, Stapleton PL, Farin FM. Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women’s Health Study. Menopause. 2006;13:902–10.PubMedCrossRef

19.

Hatzi E, Bouba I, Galidi A, Lazaros L, Xita N, Sakaloglou P, Kolios G, Bairaktari E, Kaponis A, Zikopoulos K, Tsatsoulis A, Georgiou I. Association of serum and follicular SHBG levels and SHBG (TAAAA)n polymorphism with follicle size in women undergoing ovarian stimulation. Gynecol Endocrinol. 2011;27:27–32.PubMedCrossRef

20.

Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype. Eur J Endocrin. 2008;158:861–5.CrossRef

21.

Lazaros L, Xita N, Kaponis A, Hatzi E, Plachouras N, Sofikitis N, Zikopoulos K, Georgiou I. The association of aromatase (CYP19) gene variants with sperm concentration and motility. Asian J Androl. 2011;13:292–7.PubMedCrossRef

22.

Berstein LM, Imyanitov EN, Kovalevskij AJ, Maximov SJ, Vasilyev DA, Buslov KG, Sokolenko AP, Iyevleva AG, Chekmariova EV, Thijssen JH. CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett. 2004;207:191–6.PubMedCrossRef

23.

Stratakis CA, Vottero A, Brodie A, Kirschner LS, DeAtkine D, Lu Q, Yue W, Mitsiades CS, Flor AW, Chrousos GP. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metabol. 1998;83:1348–57.CrossRef

24.

Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, Speizer FE, Hunter DJ. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer. 2000;87:204–10.PubMedCrossRef

25.

Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004;13:94–101.PubMedCrossRef

26.

Scott Jr RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril. 1995;63:1–11.PubMed

27.

Zirilli L, Rochira V, Diazzi C, Caffagni G, Carani C. Human models of aromatase deficiency. J Steroid Biochem Mol Biol. 2008;109:212–8.PubMedCrossRef

28.

Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305–9.PubMedCrossRef

29.

Zambrano E, Zarinan T, Olivares A, Barrios-de-Tomasi J, Ulloa-Aguirre A. Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems: implications for the structure-function relationship of the FSH variants. Endocrine. 1999;10:113–21.PubMedCrossRef

30.

de Koning CH, Benjamins T, Harms P, Homburg R, van Montfrans JM, Gromoll J, Simoni M, Lambalk CB. The distribution of FSH receptor isoforms is related to basal FSH levels in subfertile women with normal menstrual cycles. Hum Reprod. 2006;21:443–6.PubMedCrossRef

31.

Britt KL, Drummond AE, Cox VA, Dyson M, Wreford NG, Jones ME, Simpson ER, Findlay JK. An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene. Endocrinology. 2000;141:2614–23.PubMedCrossRef

32.

Bedaiwy MA, Mousa NA, Esfandiari N, Forman R, Casper RF. Follicular phase dynamics with combined aromatase inhibitor and follicle stimulating hormone treatment. J Clin Endocrinol Metabol. 2007;92:825–33.CrossRef

33.

Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metabol. 1999;84:2951–6.CrossRef

34.

Richards JS. Maturation of ovarian follicles: actions and interactions of pituitary and ovarian hormones on follicular cell differentiation. Physiol Rev. 1980;60:51–89.PubMed

35.

Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev. 1996;17:121–55.PubMed

36.

Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83.PubMedCrossRef

37.

Seifer DB, Maclaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. 2007;88:539–46.PubMedCrossRef

38.

Luo W, Wiltbank MC. Distinct regulation by steroids of messenger RNAs for FSHR and CYP19A1 in bovine granulosa cells. Biol Reprod. 2006;75:217–25.PubMedCrossRef

Titel: Aromatase (CYP19) gene variants influence ovarian response to standard gonadotrophin stimulation
verfasst von: Leandros A. Lazaros
Elissavet G. Hatzi
Nectaria V. Xita
Georgios V. Makrydimas
Apostolos I. Kaponis
Atsushi Takenaka
Ioannis P. Kosmas
Nikolaos V. Sofikitis
Theodoros I. Stefos
Konstantinos A. Zikopoulos
Ioannis A. Georgiou
Publikationsdatum: 01.02.2012
Verlag: Springer US
Erschienen in: Journal of Assisted Reproduction and Genetics / Ausgabe 2/2012
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-011-9673-y

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Aromatase (CYP19) gene variants influence ovarian response to standard gonadotrophin stimulation